CME Presentations

Spinal Muscular Atrophy


Presentations


Speakers

  • Nancy L. Kuntz, MD

    Nancy L. Kuntz, MD

    Nancy L. Kuntz, MD

    Professor of Pediatrics and Neurology

    Nancy L. Kuntz, MD, is a professor of pediatrics and neurology at the Northwestern Feinberg School of Medicine in Chicago, Illinois, medical director of the Mazza Foundation Neuromuscular Program, and director of the MDA Care Center at the Ann & Robert H. Lurie Children’s Hospital of Chicago. Her clinical interests include early diagnosis of neuromuscular disorders and developing less invasive methods of neuromuscular diagnosis in children, such as electrical impedance myometry, ultrasound, nerve excitability, and motor unit mapping. Dr Kuntz is the site principal investigator in numerous natural history and clinical treatment trials for neuromuscular disorders that include spinal muscular atrophy, Duchenne and Becker muscular dystrophies, and X-linked myotubular myopathy.
  • Julie A. Parsons, MD

    Julie A. Parsons, MD

    Julie A. Parsons, MD

    Professor of Clinical Pediatrics and Neurology

    Julie A. Parsons, MD, is a professor of clinical pediatrics and neurology at the University of Colorado School of Medicine in Aurora, the Haberfeld Family Endowed Chair in Pediatric Neuromuscular Disorders, and co-director of the neuromuscular clinic at Children’s Hospital Colorado. Her clinical interests include neuromuscular diseases such as muscular dystrophies, spinal muscular atrophy (SMA), and myotonic dystrophies. She is an active participant and principal investigator for many clinical trials, and is a member of organizations that include the Child Neurology Society and the American Academy of Neurology. Dr Parsons earned her MD from the University of Colorado School of Medicine, followed by residencies in pediatrics and child neurology and a neuromuscular medicine fellowship.

CME Information

Advances in Spinal Muscular Atrophy Management


LEARNING OBJECTIVES

At the conclusion of this activity, participants will be able to:

  • Conduct a thorough clinical examination and genetic testing for the early and accurate diagnosis of SMA
  • Evaluate safety and efficacy data of recently available disease-modifying treatment and supportive strategies for SMA
  • Summarize the therapeutic strategies of emerging agents for SMA based on improved understanding of SMA pathophysiology

Acknowledgement

This activity is supported by an educational grant from Biogen.

Tuition

Complimentary

Accreditation Statement

The activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Albert Einstein College of Medicine and PlatformQ Health Education, LLC. Albert Einstein College of Medicine is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation Statements

Live Internet Activity

Albert Einstein College of Medicine designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Enduring Material

Albert Einstein College of Medicine designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Other Credits

The American Academy of Nurse Practitioners (AANP) and American Nurses Credentialing Center (ANCC) accept AMA PRA Category 1 Credit(s)™ from organizations accredited by the ACCME.

Date of Release/Expiration

Live Internet Activity
February 13, 2019 from 2:00 PM ET – 3:00 PM ET.

Enduring Material
The enduring material will be available from February 13, 2019 to February 13, 2020.

Intended Audience

This activity is intended for pediatric neurologists, neurologists, pediatricians, primary care physicians, internal medicine physicians, advanced practice clinicians, physical therapists, occupational therapists, and health care providers who encounter and manage patients with SMA.

Estimated Time to Complete

This activity consists of one session, which should take approximately 1 hour to complete.

Method of Participation

There are no fees to participate in this activity. To receive credit, participants must (1) read the target audience, learning objectives, and disclosure statements, (2) complete the educational activity online, and (3) complete the posttest and activity evaluation. It is estimated that this module will take approximately 1 hour to complete. To receive AMA PRA Category 1 Credits™, participants must receive a minimum score of 70% on the posttest.

Hardware/Software Requirements

Participants will need a computer with a recent version of Adobe Flash installed, as well as an internet connection sufficient for streaming media.

Faculty Disclosure

The "Conflict of Interest Disclosure Policy" of Albert Einstein College of Medicine requires that faculty participating in any CME activity and anyone in a position to influence content disclose to the audience any relationship(s) with a pharmaceutical or equipment company. Any presenter whose disclosed relationships prove to create a conflict of interest, with regard to their contribution to the activity, will not be permitted to present.

The Albert Einstein College of Medicine also requires that faculty participating in any CME activity and anyone in a position to influence content disclose to the audience when discussing any unlabeled or investigational use of any commercial product, or device, not yet approved for use in the United States.

Presenter

Nancy L. Kuntz, MD
Fees for Non-CME/CE Services: Biogen (Lectured in Australia and Japan relating to use of nusinersen in SMA patients, particularly those with advanced scoliosis and respiratory weakness, prepared own slides)
Contracted Research: Audentes, AveXis, Biogen, Cytokinetics, Pfizer, Roche, Sarepta
Medical Advisory Boards: Audentes, AveXis, Biogen, Roche, Sarepta
Will reference the following unlabeled/unapproved drugs: Risdaplan and AveXis-101

Julie Parsons, MD
Consulting Fee: AveXis, Biogen, Roche
Contracted Research: PI for AveXis, Biogen, Cytokinetics, Scholar Rock
Will reference the following unlabeled/unapproved drugs: Risdaplan and AveXis-101

Peer Reviewer

David Kaufman, MD
Has nothing to disclose relevant to this activity

Providers

Einstein-Montefiore Center for Continuing Medical Education
The Center for Continuing Medical Education (CCME) staff at Albert Einstein College of Medicine has no disclosures to report relevant to this activity.

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

PlatformQ Health Education, LLC

David Howard
Medical Director

Has nothing to disclose relevant to this activity.

Elizabeth del Nido
Program Manager

Has nothing to disclose relevant to this activity.

Discalimers (if applicable)

The material is prepared based on a review of multiple sources of information but is not exhaustive of the subject matter. Therefore, health care professionals and other individuals should review and consider other publications and materials about the subject matter other than relying solely on the information contained in this material.

The information presented at this CME program represents the views and opinions of the individual presenters, and does not constitute the opinion or endorsement of, or promotion by Albert Einstein College of Medicine, NeuroSeriesLive, PlatformQ Health Education, LLC or the program grantor. Reasonable efforts have been made to present educational subject matter in a balanced, unbiased fashion and in compliance with regulatory requirements. Each participant must use his/her personal and professional judgment when considering further application of this information, particularly as it may relate to patient diagnostic or treatment decisions including, without limitation, FDA-approved uses and any off-label uses.

Contact Information

Accreditation Support:
Please send all inquiries to: Montefiore Medical Center, CCME, 3301 Bainbridge Avenue, Bronx, New York 10467, or via phone at (718) 920-6674, or via fax to (718) 798-2336, or via email to cme@montefiore.org.

Technical Support:
For any technical issues or issues with your CME Certificate, please contact OMedLive at (877) 394-1306 or at Support@NeuroSeriesLive.com